Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Dec 21;11(1):3.
doi: 10.3390/antibiotics11010003.

Cefiderocol for Severe Carbapenem-Resistant A. baumannii Pneumonia: Towards the Comprehension of Its Place in Therapy

Emanuele Rando  1 , Francesco Vladimiro Segala  1   2 , Joel Vargas  3 , Cristina Seguiti  1   2 , Gennaro De Pascale  3 , Rita Murri  1   2 , Massimo Fantoni  1   2
Affiliations

Cefiderocol for Severe Carbapenem-Resistant A. baumannii Pneumonia: Towards the Comprehension of Its Place in Therapy

Emanuele Rando et al. Antibiotics (Basel). .

Abstract

Cefiderocol use in A. baumannii pneumonia still represents an important matter of debate. The aim of this study is to describe 13 cases of carbapenem-resistant A. baumannii (CRAB) pneumonia treated with cefiderocol in real-life practice. We retrospectively included patients with CRAB pneumonia hospitalized at Fondazione Policlinico Universitario Agostino Gemelli Hospital treated with cefiderocol either in the general ward or the intensive care unit. A total of 11 patients out of 13 had ventilator-associated pneumonia caused by CRAB, and 12/13 patients had polymicrobial infection. We found a 30-day success rate of 54%. Cefiderocol may have a role when facing severe XDR A. baumannii pneumonia. Future studies are warranted to better define its place in therapy in CRAB infections.

Keywords: A. baumannii; CRAB; cefiderocol; pneumonia.

PubMed Disclaimer

Conflict of interest statement

Authors declare no conflict of interest.

References

    1. Brink A.J. Epidemiology of carbapenem-resistant Gram-negative infections globally. Curr. Opin. Infect. Dis. 2019;32:609–616. doi: 10.1097/QCO.0000000000000608. - DOI - PubMed
    1. Cassini A., Högberg L.D., Plachouras D., Quattrocchi A., Hoxha A., Simonsen G.S., Colomb-Cotinat M., Kretzschmar M.E., Devleesschauwer B., Cecchini M., et al. Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: A population-level modelling analysis. Lancet Infect. Dis. 2019;19:56–66. doi: 10.1016/S1473-3099(18)30605-4. - DOI - PMC - PubMed
    1. European Centre for Disease Prevention and Control . Antimicrobial Resistance in the EU/EEA (EARS-Net)—Annual Epidemiological Report 2019. ECDC; Stockholm, Sweden: 2020.
    1. El Chakhtoura N.G., Saade E., Iovleva A., Yasmin M., Wilson B., Perez F., Bonomo R.A. Therapies for multidrug resistant and extensively drug-resistant non-fermenting gram-negative bacteria causing nosocomial infections: A perilous journey toward ‘molecularly targeted’ therapy. Expert Rev. Anti-infective Ther. 2018;16:89–110. doi: 10.1080/14787210.2018.1425139. - DOI - PMC - PubMed
    1. CDC . Antibiotic Resistance Threats in the United States, 2019. U.S. Department of Health and Human Services, CDC; Atlanta, GA, USA: 2019.

LinkOut - more resources